FWIW, and as I've noted before, I agree. Partly because the insurance companies will be much more erratic in their 'approval' standards and everything, including their standards and the trials results, will be less transparent (and, yes, I think that will make medical advancement and current care substantially worse).
My only hope is that Gottleib isn't too extreme in this regard. Certainly he is *wildly* better than the Silicon Valley healthcare no-nothings.
PS What I find particularly bizarre in this case is that many of the most vocal about this issue have been people who pushed extremely hard for Eteplirsen approval (even after the FDA documents came out).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.